Literature DB >> 7059310

Radiation therapy for subclinical carcinoma in cervical lymph nodes.

R Mantravadi, A Katz, R Haas, E J Liebner, D Sabato, E Skolnik, E L Applebaum.   

Abstract

Radiotherapy alone was used to treat 187 patients with a head and neck cancer and clinically uninvolved lymph nodes. Delayed lymph node metastases developed in 35 (19%) patients, and concomitant tumor at the primary site was present in 90% of them. In two (1%) of the 187 patients, delayed metastases developed in the irradiated nodes with the primary tumor controlled; both of these patients received a radiation dose of less than 5,000 rad. Metastases in supraclavicular and posterior cervical regions occurred in 4% of the patients; and these sites were not included in the original radiation fields. The following conclusions were reached: (1) a radiation dose of 5,000 rad or more can eradicate 99% of the subclinical carcinomas in lymph nodes; (2) whole-neck irradiation is not indicated in patients with N0 stage tumor; and (3) surgical resection of primary tumors alone, without added neck dissection, may be adequate if postoperative radiation therapy is planned.

Entities:  

Mesh:

Year:  1982        PMID: 7059310     DOI: 10.1001/archotol.1982.00790500044010

Source DB:  PubMed          Journal:  Arch Otolaryngol        ISSN: 0003-9977


  3 in total

Review 1.  Management of cervical metastasis.

Authors:  Eric J Lentsch
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Duplex colour Doppler sonography - role in neck metastasis.

Authors:  R Puri; V S Srinath; A L Chakravarti
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2002-07

3.  Incidence of contralateral regional failure in the electively irradiated contralateral neck of patients with head and neck squamous cell carcinoma.

Authors:  Pieter D de Veij Mestdagh; Eric van Werkhoven; Arash Navran; Jan Paul de Boer; Willem H Schreuder; Wouter V Vogel; Abrahim Al-Mamgani
Journal:  Clin Transl Radiat Oncol       Date:  2019-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.